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Background: For cell therapies to treat diabetes, it is important to produce a
sufficient number of pancreatic endocrine cells that function similarly to primary
islets. Induced pluripotent stem (iPS) cells represent a potentially unlimited source of
functional pancreatic endocrine cells. However, the use of iPS cells for laboratory
studies and cell-based therapies is hampered by their high tumorigenic potential
and limited ability to generate pure populations of differentiated cell types in vitro.
The purpose of this study was to establish a pancreatic stem cell line from iPS cells
derived from mouse fibroblasts.
Methods: Mouse iPS cells were induced to differentiate into insulin-producing cells by a
multi-step differentiation protocol, which was conducted as described previously with
minor modifications. Selection of the pancreatic stem cell was based on morphology and
Pdx1 expression. The pancreatic potential of the pancreatic stem cells was evaluated
using a reverse transcription PCR, real-time PCR, immunofluorescence, and a glucose
challenge test. To assess potential tumorigenicity of the pancreatic stem cells, the cells
were injected into the quadriceps femoris muscle of the left hindlimb of nude mice.
Results: The iPS-derived pancreatic stem cells expressed the transcription factor –Pdx1– a
marker of pancreatic development, and continued to divide actively beyond passage 80.
Endocrine cells derived from these pancreatic stem cells expressed insulin and pancreatic
genes, and they released insulin in response to glucose stimulation. Mice injected with
the pancreatic stem cells did not develop tumors, in contrast to mice injected with an
equal number of iPS cells.
Conclusion: This strategy provides a new approach for generation of
insulin-producing cells that is more efficient and safer than using iPS cells. We
believe that this approach will help to develop a patient-specific cell transplantation
therapy for diabetes in the near future.
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Production of a sufficient number of insulin-producing cells from stem cells that func-
tion similarly to primary islets is important for clinical application of stem cell therapy
to diabetes. Many studies have reported the differentiation of insulin-producing cells
from mouse embryonic stem (ES) cells and, more recently, from human ES cells [1-7].
Unfortunately, these methods involving ES cells have various limitations such as ethical
issues during the generation of the cells and immunological rejection after an© 2014 Kuise et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kuise et al. BioMedical Engineering OnLine 2014, 13:64 Page 2 of 11
http://www.biomedical-engineering-online.com/content/13/1/64allogeneic transplant. Induced pluripotent stem (iPS) cell technology has the potential
to generate patient-specific cell types including functional pancreatic endocrine cells
[8-11]. However, the use of ES and iPS cells for laboratory studies and cell-based ther-
apies is hampered by their high tumorigenic potential and limited ability to generate
pure populations of differentiated cell types in vitro.
D’Amour et al. developed a 5-step protocol for differentiation of human ES cells into
pancreatic hormone-expressing cells in 2006 [12]; this method represented a great step
forward in regenerative medicine; however, the use of ES cells in clinical practice is
problematic, as explained above. We and other groups have established mouse pancre-
atic stem cell lines using specific culture conditions [13-15]. We have also demon-
strated that young mice have a high number of pancreatic stem cells that can be
isolated, but older mice have a low number of pancreatic stem cells, and therefore are
unable to provide viable clones [16]. Similarly, human pancreatic stem cells cannot be
isolated from 20- to 60-year-old donors [17].
In this study, we established a pancreatic stem cell line from mouse iPS cells, which
have the potential for self-renewal and multipotency to generate both endocrine and
exocrine pancreatic cells.Methods
Culture conditions
Mouse iPS cells (iPS-MEF-Ng-20D-17) were provided by the RIKEN BRC through the
Project for Realization of Regenerative Medicine and the National Bio-Resource Project of
MEXT, Japan [18]. Undifferentiated iPS cells were maintained on mouse embryo fibroblast
feeder layers (STO cell line) in Dulbecco’s modified Eagle medium (DMEM; Sigma-
Aldrich, St Louis, MO, USA) supplemented with 15% (vol/vol) fetal bovine serum (FBS;
Millipore, Billerica, MA, USA), 1% nonessential amino acids (Millipore), 1% nucleosides
(Millipore), 1% penicillin/streptomycin (Sigma-Aldrich), 110 μM 2-mercaptoethanol (Life
Technologies, Tokyo, Japan), and 500 U/mL leukemia inhibitory factor (LIF; Millipore) at
37°C. Cultures were manually passaged at a 1:4–1:8 split ratio every 3–5 days.
Directed differentiation into insulin-producing cells was conducted as described previ-
ously [12], with minor modifications (Figure 1). At stage 1, cells were incubated with
25 ng/mL Wnt3a and 100 ng/mL activin A (R&D Systems, Minneapolis, MN, USA) in the
RPMI medium (Life Technologies) at 37°C for 1 day, followed by treatment with 100 ng/
mL activin A in RPMI (containing 0.2% FBS) at 37°C for 2 days. At stage 2, the cells were
incubated with 50 ng/mL FGF10 (R&D Systems) and 0.25 μM KAAD-cyclopamine
(Toronto Research Chemicals, Toronto, Ontario, Canada) in RPMI (containing 2%
FBS) at 37°C for 3 days. At stage 3, the cells were incubated with 50 ng/mL fibroblast
growth factor 10 (FGF10), 0.25 μM KAAD-cyclopamine, and 2 μM all-trans retinoic
acid (Sigma-Aldrich) in DMEM with a 1% (vol/vol) B27 supplement (Life Technologies)
at 37°C for 3 days. At stage 4, the cells were treated with 1 μM N-[N-(3,5-Difluorophena-
cetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT; Sigma-Aldrich) and 50 ng/mL
exendin-4 (Sigma-Aldrich) in DMEM with a 1% (vol/vol) B27 supplement at 37°C for
3 days. At stage 5, the cells were incubated with 50 ng/mL exendin-4, 50 ng/mL IGF-1
(Sigma), and 50 ng/mL hepatocyte growth factor (HGF; R&D Systems) in the CMRL
medium (Life technologies) with a 1% (vol/vol) B27 supplement at 37°C for 3–6 days.
Figure 1 A five-step protocol for differentiation of iPS cells to pancreatic stem cells and
hormone-expressing cells. A. Schematic representation of the differentiation procedure and protein
expression of key markers of pancreatic differentiation. Based on D’Amour’s 5-step protocol [12], this
differentiation protocol is subdivided into 5 stages, and the growth factors, medium, and range of
duration of each stage are shown. Several markers characteristic of each cell population are listed. Pancreatic
stem cells were established after induction of stages 1 and 2. Abbreviations: CYC, KAAD-cyclopamine; RA,
all-trans-retinoic acid; DAPT, γ-secretase inhibitor; Ex4, exendin-4; iPS, induced pluripotent stem cell; ME,
mesendoderm; DE, definitive endoderm; PG, primitive gut tube; PF, posterior foregut endoderm; PE,
pancreatic endoderm and endocrine precursor; EN, hormone-expressing endocrine cells. B. Morphology
of 52 clones after induction of stages 1 and 2 (passage 2). Scale bars = 200 μm.
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To examine the potential tumorigenicity of candidate clones at passage 50, 1 × 107 cells
were injected into the quadriceps femoris muscle of the left hindlimb of nude mice
(n = 3). As a positive control, we transplanted 1 × 107 iPS cells into the right hind-
limb. All mouse studies were approved by the Institutional Animal Care and Use
Committee of Okayama University (Reference number: OKU-2011351).Semi-quantitative RT-PCR
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen, Tokyo, Japan).
After the RNA was quantified using spectrophotometry, 2.5 μg of the RNA was heated
at 85°C for 3 min and then reverse-transcribed into cDNA in a 25-μL reaction contain-
ing 200 units of Superscript III RT (Life Technologies), 50 ng of random hexamer
primers (Life Technologies), 160 μmol/L dNTP, and 10 nmol/L dithiothreitol. The reac-
tion consisted of 10 min at 25°C, 60 min at 42°C, and 10 min at 95°C. PCRs were per-
formed in a Perkin-Elmer 9700 Thermocycler with 3 μL of cDNA (20 ng RNA
equivalent), 160 μmol/L cold dNTPs, 10 pmol of the appropriate oligonucleotide
primers, 1.5 mmol/L MgCl2, and 5 units of AmpliTaq Gold DNA polymerase (Perkin-
Elmer, Waltham, MA, USA). The oligonucleotide primers and cycle numbers used for
semi-quantitative PCR are shown in Table 1. The thermal cycle profile used a 10-min
denaturing step at 94 C followed by the amplification cycles (1 min denaturation at
94 C, 1 min annealing at 57 C, and 1 min extension at 72°C), with a final extension step
of 10 min at 72°C. The steps taken to validate these measurements were previously
reported [19].TaqMan real-time PCR
Quantification of Ngn3, NeuroD, and insulin-2 mRNA levels was conducted using the
TaqMan real-time PCR system according to the manufacturer’s instructions (Life Tech-
nologies). PCR consisted of 40 cycles including 2 min at 50°C and 10 min at 95°C as
initial steps. In each cycle, denaturation was performed for 15 s at 95°C and annealing/
extension was 1 min at 60°C. PCR was conducted in 20-μL reaction containing cDNA
synthesized from 1,500 ng of total RNA. Standard curves were constructed using cDNA
generated from total RNA isolated from primary mouse islets. For each sample, the
expression of Ngn3, NeuroD, and insulin-2 was normalized against the β-actin expres-
sion level. Mouse Ngn3, NeuroD, and insulin-2 and β-actin primers were obtained
commercially (Assays-on-Demand Gene Expression Products; Life Technologies).Table 1 List of gene-specific primers
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To remove insulin added to the culture medium, cultured cells were washed 10 times
with phosphate-buffered saline (PBS). The RPMI medium with a low glucose
concentration (2.8 mM) was added, and the cells were cultured at 37°C for 30 min as
preincubation. After the preincubation, RPMI with a low glucose concentration
(2.8 mM) was added, and the cells were cultured at 37°C for 60 min. This low-
glucose medium was then collected. The RPMI medium with a high glucose con-
centration (20 mM) was then added, and the cells were cultured at 37°C for 60 min.
This high-glucose medium was also collected. The collected media were assayed for
insulin concentration using an enzyme-linked immunosorbent assay (ELISA; SRL,
Tokyo, Japan).An immunofluorescence assay
Cells were fixed in 4% paraformaldehyde for 20 min. Subsequently, the cells were
blocked with 10% serum and 0.2% Triton X-100 in PBS, and then incubated with a
primary antibody against mouse insulin (guinea pig polyclonal antibody to mouse
insulin, 1:100; Abcam, Tokyo, Japan) overnight at 4°C. The cells were next incubated
with a secondary antibody (goat polyclonal antibody against guinea pig IgG, H&L
labeled with fluorescein isothiocyanate [FITC], 1:100; Abcam). A medium for fluor-
escence microscopy that contained 4′,6-diamidino-2-phenylindole (DAPI; Vector
Laboratories, Burlingame, CA, USA) was used for mounting onto slides.Results
Directed pancreatic differentiation of fibroblast-derived iPS cells
To generate pancreatic stem cells from iPS cells, we applied the D’Amour’s protocol
[12]. At stage 1, iPS cells differentiated into definitive endoderm using high concen-
trations of activin A with Wnt3a (day 1) and FBS supplementation (days 2–3). At
stage 2, the definitive endoderm cells differentiated into gut tube endoderm through
removal of activin A and addition of FGF10 and KAAD-cyclopamine. After the cells
were passaged once and cultured for 4 days, the clones were manually picked under
a dissecting microscope (Figure 1A). These clones were then cultured on STO feeder
cells in the ES culture medium. The 52 clones were cultured and passaged for 30 days
(Figure 1B). After the 30-day culture of these clones, 12 clones were still viable
(Figure 2A),Establishment of pancreatic stem cells
Among the 12 clones, 6 were eliminated because they did not proliferate as actively as
did the iPS cells. Expression of pancreatic and duodenal homeobox factor 1 (Pdx1)
mRNA, a transcription factor required for pancreatic development and β-cell matur-
ation, in the remaining 6 clones is shown in Figure 2B. The proliferative activity of 4 of
the 6 clones significantly decreased during a 60-day culture after the isolation. There-
fore, we selected the 2 clones (C#15 and D#22) that maintained a constant cell prolifer-
ation rate as candidate clones for differentiation into pancreatic stem cells. Clone C#15
was ascertained to have a tumorigenic potential. Finally, clone D#22 was selected
(Figure 2C). D#22 cells did not express green fluorescent protein (GFP), whereas the
Figure 2 Morphology and expression of Pdx1 and Nanog, and growth activity. A. Morphology of 12
clones after 30-day culture (passage 7). Scale bars = 200 μm. B. Pdx1 gene expression of 6 candidate clones.
These 6 clones were selected based on their ability to grow in culture for over 30 days. Pancreatic stem
cells from pancreatic tissue (data not shown) were used as a positive control. C. Nanog (GFP) expression of
D#22 and iPS cells. The iPS cells but not D#22 cells expressed GFP. D. Morphology of D#22 cells at several
passages. Scale bars = 200 μm. E. Growth activity of D#22 cells at passages 10 and 50.
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suggests that D#22 cells do not express Nanog and are therefore different from iPS
cells (Figure 2C).Morphology, gene expression, and growth activity of the pancreatic stem cell line D#22
Clone D#22 formed a flat “cobblestone” monolayer, which is characteristic of cultured
duct cells [20]. D#22 cells continued to divide actively beyond passage 80 (over 6 months)
without changes in morphology (Figure 2D) or in growth activity (Figure 2E). We per-
formed normal and quantitative RT-PCR testing of clone D#22 for ES cell markers, endo-
dermal/pancreatic progenitor cell markers, and pancreatic cell markers. Mouse pancreas
cDNA and iPS cells were used as controls. Representative genes of the posterior foregut
(Pdx1) and pancreatic endoderm (Ngn3, NeuroD) were expressed by clone D#22, whereas
genes typically expressed in undifferentiated iPS cells (Nanog) and in pancreatic tissue
(insulin, glucagon, amylase, and somatostatin) were not expressed in D#22 (Figure 3A, B).
Figure 3 Characterization of the pancreatic stem cell line D#22. A. RT-PCR analysis of expression of an
ES cell marker (Nanog), pancreatic progenitor markers (Pdx1), and mature pancreatic markers (insulin-2,
glucagon, amylase, and somatostatin) in D#22 cells. Pancreatic cells and iPS cells were used as controls. The
primers used for RT-PCR are shown in Table 1. B. Quantitative RT-PCR analysis of the Ngn3 and NeuroD
genes in iPS, D#22, and pancreatic cells. The data are expressed as the Ngn3 and NeuroD to β-actin ratio,
with the expression in D#22 cells arbitrarily set at 1.0. C. Morphology of D#22 stage 5 cells and iPS stage 5
cells. Scale bars = 200 μm. D. Quantitative RT-PCR analysis of the insulin-2 gene in D#22 stage 5 cells and
iPS stage 5 cells. Differentiated cells derived from D#22 cells by stages 3–5 or iPS cells by stages 1–5 were
analyzed using quantitative RT-PCR. The data are expressed as the insulin-2 to β-actin ratio, with the expression
in iPS stage 5 cells arbitrarily set at 1.0. E. RT-PCR testing for pancreatic markers of maturity (glucagon, amylase,
and somatostatin) in D#22 stage 5 and iPS stage 5 cells. Pancreatic cells were used as a control. The primers
used for RT-PCR are shown in Table 1.
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For differentiation of D#22 cells into insulin-producing cells, the following protocols
were used (stages 3–5 in Figure 1A). At the final stage of differentiation, D#22 cells
underwent a morphological transition (Figure 3C). The differentiated cells derived from
D#22 cells, named D#22 stage 5 cells, were tested for pancreas-specific gene expression
and insulin production. Mouse iPS cells were also induced to differentiate using the
5-step protocol (Figure 1); the pancreatic potential of the final product (iPS stage 5
Kuise et al. BioMedical Engineering OnLine 2014, 13:64 Page 8 of 11
http://www.biomedical-engineering-online.com/content/13/1/64cells) was compared with that of D#22 stage 5 cells. Quantitative PCR demonstrated
that levels of insulin 2 mRNA were 8.46-fold higher in D#22 stage 5 cells than in iPS
stage 5 cells (Figure 3D). D#22 stage 5 cells were positive for gene expression of hor-
mones produced in the endocrine pancreas (e.g., insulin, glucagon, and somatostatin)
in addition to a representative enzyme produced in the exocrine pancreas (amylase;
Figure 3E).Insulin expression and functional analysis of D#22 stage 5 cells
To determine whether D#22 cells could differentiate into insulin-producing cells, im-
munofluorescence analysis was performed. Some D#22 stage 5 cells were positive for
insulin, and the insulin-positive cells were C-peptide positive, thus excluding the possi-
bility of insulin uptake from the medium (Figure 4A).
To evaluate the insulin production of D#22 stage 5 cells, a glucose challenge test was
performed in vitro. The amount of insulin secreted by D#22 stage 5 cells tended to
increase when the glucose concentration of the medium was high, whereas iPS stage
5 cells showed little or no response to the glucose challenge (Figure 4B). These data
suggested that D#22 stage 5 cells had the ability to secrete insulin in response to the
pathological glucose concentrations similar to those in diabetic patients.Tumorigenicity of the pancreatic stem cell line D#22
To rule out the possibility of teratoma formation as a result of contamination with iPS
cells or spontaneous transformation of D#22 cells, the tumorigenic potential was tested
in vivo. D#22 cells (1 × 107) at passage 50 were transplanted into nude mice (n = 3), and
no tumors developed after 2 months. In contrast, injection of 1 × 107 iPS cells resulted
in tumor development after 2 weeks. Tumors derived from the iPS cells became larger
over time and had a size of 40 mm at 2 months after transplantation (Figure 4C).Discussion
In this study, we established a pancreatic stem cell line, D#22, from mouse fibroblast-
derived iPS cells. Generally, stem cells are defined as cells capable of self-renewal that
can develop into various lineages in the body. D#22 cells were maintained by repeated
passaging for more than 6 months without growth inhibition, which indicates that
D#22 cells have the potential for self-renewal. The differentiated D#22 stage 5 cells
express insulin, glucagon, amylase, and somatostatin mRNA; these data indicate that
D#22 cells can generate both endocrine and exocrine pancreatic lineages. Conse-
quently, we consider the clone D#22 a pancreatic stem cell line. As shown in Figure 3A,
D#22 cells express Pdx1, Ngn3, and NeuroD. Pdx1-expressing epithelial progenitors are
involved in the development of organs during embryogenesis, especially the cells giving
rise to the endocrine, exocrine, and ductal cells of the pancreas [21]. Ngn3 is expressed
in all endocrine progenitors [21], initiating a cascade of expression of transcription
factors that control endocrine cell differentiation. NeuroD, a basic helix-loop-helix
(bHLH) transcription factor, is also a key regulator of pancreatic islet morphogenesis
and insulin gene transcription [22,23]. However, D#22 cells did not express key tran-
scription factors of ES cells (Nanog) or mature pancreatic cells (insulin, glucagon,
Figure 4 Insulin expression and teratoma formation/tumorigenicity assay of the pancreatic stem
cell line D#22. A. Immunofluorescence analysis of differentiated cells derived from D#22 cells. Insulin and
C-peptide staining of D#22 stage 5 cells was performed. Scale bars = 200 μm. B. Insulin release assay. D#22
stage 5 cells and iPS stage 5 cells were stimulated with D-glucose at 2.8 mM and 20 mM, and the amount
of insulin released into the culture supernatant was measured using ELISA. Error bars represent standard
error. C. In total, 1 × 107 of D#22 cells were injected into the thigh of nude mice. As a positive control, we
transplanted 1 × 107 iPS cells into the contralateral thigh.
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of pancreatic endoderm-committed intermediates or pancreatic progenitors.
D#22 stage 5 cells secreted insulin in response to glucose stimulation, and immu-
nofluorescent analysis of the differentiated cells showed production of insulin and
C-peptide. Moreover, in the real-time PCR analysis, mRNA expression of insulin 2 was
8.46-fold higher in D#22 stage 5 cells than in iPS stage 5 cells generated using the same
stepwise differentiation protocol. In addition, clone D#22 is not tumorigenic, whereas
transplanted iPS cells rapidly form tumors. In general, tumorigenesis is a major concern
in the clinical application of stem cell therapy. Therefore, we can conclude that D#22
cells are potentially a more useful cell source for β-cell replacement therapy in diabetes
than iPS cells because the former are safer and capable of generating greater numbers
of functional insulin-producing cells. Nevertheless, the level of insulin expression was
still low; suggesting that the induced cells were still immature. Therefore, it is necessary
to develop a more efficient differentiation protocol for production of insulin-producing
cells.
The advantages of D#22 cells compared with iPS cells are 1) more efficient differenti-
ation, and 2) no teratoma formation. Recently, a self-renewing endodermal progenitor
(EP) cell line generated from human ES and iPS cells was reported [24]. The self-
renewing EP cells display morphological properties and a gene expression pattern
characteristic of a definitive endoderm. These EP cells differentiate into pancreatic
cells, hepatocytes, and intestinal epithelial cells. Moreover, EP cells are not tumori-
genic in vivo. D#22 cells may be similar to EP cells, but are likely to be differentiated
further into the pancreatic linage because they express the Pdx1, Ngn3, and NeuroD
transcription factors.
Conclusions
We established a mouse pancreatic stem cell line from iPS cells derived from mouse
embryonic fibroblasts. This clonal cell line has the ability of self-renewal and efficiently
differentiates into insulin-producing cells without any signs of tumorigenesis. There-
fore, this strategy provides a new approach for generation of insulin-producing cells
more efficiently and safely compared to iPS cells. We believe that this approach will
help implement a patient-specific cell transplantation therapy for diabetic patients in
the near future.
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